B
Bradley J. Monk
Researcher at St. Joseph Hospital
Publications - 39
Citations - 4435
Bradley J. Monk is an academic researcher from St. Joseph Hospital. The author has contributed to research in topics: Radical Hysterectomy & Bevacizumab. The author has an hindex of 23, co-authored 39 publications receiving 3790 citations. Previous affiliations of Bradley J. Monk include Texas Tech University Health Sciences Center & University of California, Irvine.
Papers
More filters
Journal ArticleDOI
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
William A. Peters,P. Y. Liu,Rolland J. Barrett,Richard J. Stock,Bradley J. Monk,Jonathan S. Berek,Luis Souhami,Perry Grigsby,William Gordon,David S. Alberts +9 more
TL;DR: The addition of concurrent cisplatin-based CT to RT significantly improves progression-free and overall survival for high-risk, early-stage patients who undergo radical hysterectomy and pelvic lymphadenectomy for carcinoma of the cervix.
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer EDITORIAL COMMENT
Robert A. Burger,Mark F. Brady,Michael A. Bookman,Gini F. Fleming,Bradley J. Monk,Helen Huang,Robert S. Mannel,Howard D. Homesley,Jeffrey M. Fowler,Benjamin E. Greer,Matthew P. Boente,Michael J. Birrer,Sharon X. Liang +12 more
TL;DR: The use of bevacizumab during and up to 10 months after carboplatin and paclitaxel chemotherapy prolongs the median progression-free survival by about 4 months in patients with advanced epithelial ovarian cancer.
Journal ArticleDOI
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
William A. Peters,P. Y. Liu,Rolland J. Barrett,Richard J. Stock,Bradley J. Monk,Jonathan S. Berek,Luis Souhami,Perry Grigsby,William Gordon,David S. Alberts +9 more
TL;DR: In this paper, the authors evaluated whether the addition of cisplatin-based chemotherapy (CT) to pelvic radiation therapy (RT) will improve the survival of early-stage, high-risk patients with cervical carcinoma.
Journal ArticleDOI
Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer.
TL;DR: BEV is generally well tolerated after multiple prior cytotoxic regimens and results in significant clinical benefit among women with recurrent ovarian cancer.
Journal ArticleDOI
Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy
TL;DR: Radical hysterectomy and tailored adjuvant radiation therapy in stage IB2 cervical cancer is feasible and survival in this high-risk group compares favorably to primary chemotherapy and radiation.